Gastric Cancer News and Research

RSS

FDA approves Cyramza to treat patients with advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

Researchers provide new blood test for early detection of stomach cancer

University of Adelaide research has provided new hope for the early detection of stomach cancer with the identification of four new biomarkers in the blood of human cancer patients.

18 Mar 2014

Scientist receives AGA-GCF Research Scholar Award for research in gastric, esophageal cancer

The American Gastroenterological Association (AGA) Research Foundation and the Gastric Cancer Foundation (GCF) are pleased to announce that the first AGA-Gastric Cancer Foundation Research Scholar Award in Gastric and Esophageal Cancer will support Mohamed El-Zaatari, PhD, from University of Michigan, as he conducts research into the role of myeloid cells in the transition from chronic inflammation to gastric pre-neoplasia.

12 Mar 2014

Dyax reports total revenues of $16.9 million for fourth quarter 2013

Dyax Corp. today announced financial results for the fourth quarter and year ended December 31, 2013.

28 Feb 2014

Pathway Genomics announces launch of Hereditary Colorectal Cancer DNA Insight genetic test

Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services worldwide, today announced the launch of Hereditary Colorectal Cancer DNA Insight, the company's premier hereditary cancer genetic test. Based on a simple saliva sample, the test uses next-generation sequencing (NGS) technology to identify gene alterations or mutations that increase a patient's risk of developing certain types of cancer.

18 Feb 2014

New scientific article shows that Patrys' PAT-SC1 safe, well-tolerated in gastric cancer patients

Patrys Limited, a clinical stage biotechnology company is pleased to announce the publication of a new scientific article regarding its product PAT-SC1 in the Oncology Reports journal. The article is currently available online and will be included in a future print edition of the journal.

22 Jan 2014

University of Liverpool awarded £3.2 million to develop new diagnostic tests for cancers

The University of Liverpool has been awarded -3.2 million to develop new diagnostic tests for cervical, oesophageal and prostate cancer patients.

21 Jan 2014

Research shows how coevolution between humans and bacteria can affect gastric cancer risk

Research carried out in two distinct communities in Colombia illustrates how coevolution between humans and bacteria can affect a person's risk of disease. Working with colleagues in Columbia and the U.S., Scott Williams, PhD, a professor of genetics at the Geisel School of Medicine at Dartmouth, and his graduate student Nuri Kodaman discovered that the risk of developing gastric cancer depends heavily on both the ancestry of the person and the ancestry of Helicobacter pylori with which that person is infected.

15 Jan 2014

International researchers study glycans that could help clinicians diagnose gastric cancer early

Gastric cancer kills more than 700,000 people each year, mostly in Latin America, Asia and Eastern Europe. Though the disease is quite treatable when caught early, symptoms are indistinct and late detection leads to high mortality. The five-year survival rate in the United States is 26.9 percent.

22 Dec 2013

Researchers develop oral vaccine against Helicobacter pylori

Researchers from Southern Medical University in Guangdong, Guangzhou, China, have developed an oral vaccine against Helicobacter pylori, the bacteria responsible for peptic ulcers and some forms of gastric cancer, and have successfully tested it in mice. The research is published ahead of print in the journal Clinical and Vaccine Immunology.

20 Dec 2013

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of a placebo-controlled, randomized, phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Special issue on Helicobacter pylori provides new insights into diagnosis, prevention and treatment

A special issue on Helicobacter pylori has been published by Landes Bioscience (Austin, TX USA). The articles contained in this special issue of the journal Gut Microbes have been authored by world-class investigators and provide new insights into the pathophysiology, diagnosis, prevention, and treatment of this microbe.

20 Nov 2013

immatics, Roche enter into cancer vaccine and immunotherapy deal

immatics biotechnologies GmbH and Roche today announced a strategic research and development collaboration covering multiple cancer vaccines and immunotherapeutics.

13 Nov 2013

Peptide from cow's milk exhibits potent anticancer capability against human stomach cancer cell cultures

New research from a team of researchers in Taiwan indicates that a peptide fragment derived from cow's milk, known as lactoferricin B25 (LFcinB25), exhibited potent anticancer capability against human stomach cancer cell cultures.

8 Nov 2013

Lactoferricin B25 derived from cow's milk shows promise for treatment of gastric cancer

8 Nov 2013

Imugene Acquiring Biolife, As Lead Pipeline Candidate Nears Phase II

...

23 Oct 2013

FDA grants Priority Review to Lilly's ramucirumab for treatment of advanced gastric cancer

Eli Lilly and Company today announced that the U.S. Food and Drug Administration has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy.